Amprologix Presents at ESCMID Global 2025
16 April 2025Mat Upton, CSO, presented the latest results from ongoing research at ESCMID Global 2025. ESCMID Global 2025 - the Congress of…
Mat Upton, CSO, presented the latest results from ongoing research at ESCMID Global 2025. ESCMID Global 2025 - the Congress of…
Mat Upton, CSO, presented new data at the 9th AMR conference in Basel on 25th February. It was suggested that…
Amprologix will be attending the Investival Showcase in London on 18th November 2024 Amprologix will be attending the Investival Showcase in…
Amprologix files the first of a new series of patents protecting novel molecular structures for the treatment of bacterial infections.…
Innovate UK has awarded Amprologix £1M of Biomedical Catalyst funding to continue the Tobraderm project 1st March 2024 Amprologix is…
Having been based in the Marine Building at Plymouth University for the last 2-years, the company is now moving to the Derriford Research Facility to accommodate our expansion plans as we transition into the clinical phase of our antibiotic discovery programmes.
Amprologix CSO collaborates with Dr Max Ryadnov from the UK’s National Physical Laboratory, to publish new data on the novel mode of action of epidermicin NI01. Findings are reported in the August issue of iScience.
